REG - Scancell Hlds - Scancell presenting at AACR IO conference

Scancell HoldingsAnnouncement

17/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250217:nRSQ2545Xa&default-theme=true

RNS Number : 2545X  Scancell Holdings Plc  17 February 2025

17 February 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell to present translational data from the Phase 2 ongoing SCOPE trial of
SCIB1 at the 2025 AACR IO conference

 

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy
products for the treatment of multiple cancers, announce translational data
from the SCOPE trial demonstrating SCIB1 combined with nivolumab and
ipilimumab  will be presented during a poster session at the AACR IO
(https://www.aacr.org/meeting/aacr-io-discovery-and-innovation-in-cancer-immunology-revolutionizing-treatment-through-immunotherapy/)
conference, taking place in Los Angeles, California on 23-26 February 2025.

 

SCIB1, a DNA plasmid melanoma cancer vaccine, is the lead product from the
Company's ImmunoBody® DNA Vaccine platform, which uses the body's immune
system to identify, attack and destroy tumours. The SCOPE Study (NCT04079166)
is a Phase 2, Multicentre Open-Label, Study, investigating SCIB1 with double
checkpoint inhibitors ("CPIs") in late-stage melanoma. So far, 25 patients in
cohort 1, receiving SCIB1 in combination with ipilimumab and nivolumab, have
shown 84% disease control rate, 80% progression free survival and 20% complete
response rate. The translational data that will be presented demonstrates
functional vaccine specific T cell responses for patients enrolled in cohort 1
(SCIB1 plus ipilimumab and nivolumab).

 

Phil L'Huillier, Chief Executive Officer, Scancell, commented: "Presenting
data showing vaccine specific T cell responses at AACR IO is an important
validation of SCIB1 efficacy in advanced melanoma. This data supports the
latest findings from the Phase 2 Scope trial, evaluating SCIB1 in combination
with CPIs. We look forward to sharing the latest insights with leading
industry experts at AACR IO."

 

Poster presentation details are as follows:

 

Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab +
ipilimumab induces functional CD4 and CD8 T cell responses in patients with
advanced unresectable melanoma.

Poster no.: B119

Session type: Poster session B

Session date and time: 25 February 2025, 13:45-16:45 PT

Location: Platinum Ballroom A-J

Speaker: Joseph Chadwick

Authors: Joseph Chadwick, Gaëlle Cane, Sabaria Shah, Katie Mann, Patrick
Copeland, Daisy Weston, Jordan Wright, Leanne Toon, Heather Shaw, Poulam
Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare
Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples, Kate Young, Pippa
Corrie, Robert Miller, Rachael Metheringham, Georgia Goodhew, Nermeen
Varawalla, Samantha Paston and Lindy Durrant.

 

 

If you would like to arrange a meeting at the conference, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

 

 For further information, please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO
 Sath Nirmalananthan, CFO
 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang, Satheesh Nadarajah

 ICR Healthcare                                          +44 (0) 20 3709 5700

 Mary-Jane Elliott, Angela Gray, Stephanie Cuthbert      scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

 

 

About SCIB1/iSCIB1+

 

SCIB1 is the lead product from the Company's ImmunoBody® DNA Vaccine
platform, which uses the body's immune system to identify, attack and destroy
tumours. iSCIB1+ is a modified version of SCIB1 developed using Scancell's
AvidiMab® platform to enhance its potency compared to SCIB1. iSCIB1+ also
includes additional melanoma-specific epitopes so it has the potential to be
effective in a broader patient population beyond the 40% of patients with the
tissue type treatable with SCIB1, where treatment is human leukocyte antigen
(HLA) dependent.

 

About the SCOPE Study

 

The SCOPE Study (NCT04079166
(https://clinicaltrials.gov/study/NCT04079166?term=scib1&rank=2) ) is a
Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in
Patients With Advanced Unresectable Melanoma Receiving Nivolumab With
Ipilimumab or SCIB1 With Pembrolizumab to determine the response rate and
safety and tolerability of intramuscular SCIB1 or iSCIB1+ when added to
nivolumab (Opdivo) with ipilimumab (Yervoy) or SCIB1 with pembrolizumab
(Keytruda). Conducted across approximately 15 sites in the United Kingdom,
this multi-site trial aims to demonstrate durable and potent anti-tumour
activity and ORR of SCIB1/Iscib1+ in addition to standard of care checkpoint
inhibitors. Additional endpoints include duration of response (DOR),
progression free survival (PFS), overall survival (OS), safety, and
tolerability. Participants receive up to 10 doses of either SCIB1 or
iSCIB1+ using PharmaJet Stratis® needle-free injection device system in the
upper arm or upper leg. up to 85 weeks, in combination with nivolumab with
ipilimumab or SCIB1 with pembrolizumab. More information on this trial can
be found at clinicaltrials.gov
(https://www.globenewswire.com/Tracker?data=kFdkwwLSgbD6z3fn9vUCka0Qz0AJKqFORBMc75T9h3-ujhX_zVQAo_xfzHMq1VSVaSwzYC-I4BJQN091N6PmYaksDhJ1Zxmuq5mzXzNqNFmb1OF68oHsNmON1xEoQHNN)
 or www.clinicaltrialsregister.eu
(https://www.globenewswire.com/Tracker?data=xr5c6tg-TO35E29FgLlaybp84b5tzMcxFBAWSK6wNjjVV9lFuc0E-ved76qXQ6iE3li1AgSKKhIzCZ7ZVeGWf0BwH1imiXxE1qEd6o-HwfgHdY4-D7q9cstA7wq7LA7s)
.

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.  Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise damaged or
infected cells. In order to destroy such cancerous or infected cells, Scancell
uses either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique approach is
that its innovative products target modifications of proteins and lipids. For
the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and
homocitrullination of proteins, whereas its mAb portfolio targets glycans or
sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances
the potency of antibodies and their ability to directly kill tumour cells
(AvidiMab® ).

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFITFSISLIE